Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAE versus DEB-TACE for unresectable hepatocellular carcinoma
2018-000740-25Phase 3Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Time to progression. Started Sep 2021; status: completed.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-000740-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000740-25.